Bronchiolitis obliterans syndrome (BOS) is a form of chronic lung allograft dysfunction that
affects a majority of lung transplant recipients and is the principal factor limiting long-term …

Objectives: Bronchiolitis obliterans is the greatest limitation to the long-term applicability of
lung transplantation. Although alloimmune events are important, nonimmune events, such …

Lung transplantation is the treatment option for a variety of end-stage pulmonary diseases.
Posttransplant development of Abs against donor HLA and non-HLA Ags have been …

Until recently, allograft rejection was thought to be mediated primarily by alloreactive T cells.
Consequently, immunosuppressive approaches focused on inhibition of T cell activation …

Bronchiolitis obliterans syndrome (BOS) represents a major limitation in lung
transplantation. While acuterejection is widely considered the most important risk factor for …

BACKGROUND: The impact of HLA-specific antibodies is not well established in the acute
rejection of lung allografts. Acute rejection represents the most important risk factor for the …

Development of anti-HLA class I antibodies is associated with bronchiolitis obliterans
syndrome (BOS) after lung transplantation. BOS is characterized histologically by significant …

Lung transplantation is recognized as the only viable treatment option in a variety of end‐
stage pulmonary diseases. However, the long‐term survival after lung transplantation is …

Long-term success in lung transplantation continues to be challenged by chronic graft
dysfunction, which is manifest as bronchiolitis obliterans syndrome (BOS). The mechanisms …

Background. A number of genetic polymorphisms have been shown to regulate the
production and secretion of tumor necrosis factor (TNF)-α, transforming growth factor (TGF) …